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Abstract
Allergic diseases are the most prevalent immunopathologies worldwide. 
Nowadays, allergen avoidance is the unique effective treatment for allergic 
patients. Pre-clinical studies and clinical trials have been successful to prove 
that immunotherapies may accomplish mucosal mechanisms of allergen-
specific tolerance, which are able to revoke the allergic sensitization. 
Although more than 100 years have elapsed since the first reported procedure 
achieved in patients sensitive to pollen, the main obstacle in these therapies 
still remains adverse reactions induced during treatment. The need for further 
studies is required to explore safe and effective therapeutic protocols. More 
recently, immunotherapy appears to be an attractive option for patients with food 
allergy, although it is still experimental. Different strategies were proposed to 
overcome the concerning adverse effects that compromise safety, effectiveness 
and compliance with treatments. At this point, translational medicine is a flourish 
field in the arenas of basic science, applied science, and clinical research. The 
use of experimental animals may provide new insights to unravel mechanisms 
that play key roles in desensitization and tolerance induction, and to modify 
existing protocols or design new therapeutic approaches. The present reviews 
describes the different immunotherapies that are used in allergic patients, the 
promising immune interventions that are currently evaluated in clinical trials 
and the contributions that animal models may provide to improve the quality of 
treatments.
cell-mediated immune response underlying the detrimental reaction 
to the innocuous food. 
Diagnosis of food allergy is complicated. It is a heterogeneous 
disorder involving several clinical entities with no single immunologic 
mechanism involved. Once food allergy is suspected the first 
clinical or even familial indication is avoidance of the suspicious 
food. Currently, there is no accepted form of therapy for food 
allergies. Patient and family should be educated to avoid exposure 
to the responsible allergen, and they should have immediate access 
to epinephrine in case of anaphylaxis when accidental ingestion 
occurred. In addition, there are no therapies proven to accelerate the 
development of oral tolerance or provide effective protection from 
accidental exposures. However, novel allergen specific and allergen 
non-specific approaches to food allergy therapy are under study [7].
Immunotherapy is nowadays a treatment procedure to induce, 
enhance or suppress an immune response in different immunological 
disorders (cancer, autoimmunity, allergy, etc). Although allergen 
specific immunotherapy has been used for the treatment of IgE-
mediated allergy longer than a hundred years, the first randomized 
clinical trial of oral immunotherapy for food allergy was done in 
2008. Of note, this therapeutic procedure has not been accepted as a 
routine treatment for food allergy.
The aim of food allergy immunotherapy is to step-wise induce 
desensitization followed with a permanent restoration of oral 
tolerance. The term desensitization accounts for a temporary hypo-
responsiveness during regular ingestion of the food, as dosing is 
Introduction 
Allergic diseases are a global health concerning and result from a 
complex interaction between environmental factors and genes. Food 
allergy is an immune-mediated adverse reaction against antigenic 
foods and constitutes a growing clinical problem. As incidence of 
allergy escalated during the last decades in some highly industrialized 
regions, the prevalence of food allergy has raised at the same time 
mainly in infancy [1,2] and is becoming a growing issue in adults [3]. 
Despite the great progress made to elucidate the molecular basis 
of allergic disorders, it is not completely understood why some 
individuals develop allergic sensitization to some foods, while the 
majority of individuals are immunologically tolerant. In this regard 
evidence suggests that environmental factors are key inducers 
[4]. Although any food is potentially capable of causing an allergic 
reaction, a group of eight major allergenic foods, referred to as the 
“Big 8”, account for 90 % of all food allergic reactions in The United 
States. These are: peanut, tree nuts, cow’s milk, egg, soybean, wheat, 
fish and shellfish and its derivatives. Recent evidences may explain 
why certain foods are inherently allergenic [5,6].
A variety of symptoms involving the skin, gastrointestinal 
and respiratory tracts can be evidenced in allergic patients upon 
exposure to the offending food; these symptoms can be attributed to 
IgE-mediated and/or non-IgE mediated mechanisms. Genetic pre-
disposition, environmental factors, route of exposure and maturity 
of the mucosal immune system may play a role in sensitization rather 
than oral tolerance to foods, leading to a Th2-biased food specific T 
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discontinued, the protective effect is lost. Tolerance is defined as a 
prolonged ability to ingest large amounts of food proteins with no 
detrimental reaction, being immunotherapy completed. Different 
reports describe advances made in oral, sublingual and subcutaneous 
food immunotherapies, with some approaches and innovations 
derived from animal model studies [8].
In this sense, mouse models of allergic diseases provide an 
essential tool for studying the pathogenesis of allergic diseases, and 
the development of novel or modified therapeutic strategies. As 
mice do not develop allergy spontaneously, it is induced artificially 
through the use of pro-Th2 adjuvants (aluminum hydroxide, cholera 
toxin, Staphylococcus enterotoxin B, etc.). The artificial sensitization 
method employed limited the use of these experimental animals to 
study the inductive phase of food allergy. During the sensitization 
phase, the repeated intragastric administration of food proteins 
in combination with a potent mucosal adjuvant, cholera toxin, 
abrogates oral tolerance to the co-administered antigens, and 
establishes the disease state, which can be easily evidenced with the 
clinical signs elicited minutes after the exposure to the food allergen 
[9,10]. A variety of in vitro and in vivo parameters can be evaluated 
to characterize the allergic status of sensitized mice [10-12]. These 
experimental models have been successfully employed to explore 
the effects of different immunotherapeutic strategies on the immune 
system. The ability to sensitize animals to a specific food through the 
intragastric administration of allergens, and then elicit an allergic 
response by activating mucosal immune cells provides clear ties to 
the human condition. In addition, mouse models constitute useful 
biological tools to study novel mucosal adjuvants, both to induce 
a Th2 immunoregulatory immune response for Th1-mediated 
immunopathologies (autoimmunity), and to modulate it (allergic 
disorders). 
Oral immunotherapy
Oral immunotherapy (OIT) consists in a daily consumption of 
milligrams to grams of the selected allergen, which is incrementally 
raised over weeks to months with the goal of inducing desensitization 
and then tolerance [13-15]. In the first randomized double-blind 
placebo-controlled OIT trial performed by Skripak et al., 20 children 
with IgE-mediated cow’s milk allergy were randomized given milk 
or placebo. The main point of this study was that patients tolerated 
128 times higher amounts of milk compare with patients before 
treatment or with placebo-treated patients [15]. Despite no variation 
on serum specific IgE levels, IgG4 and titration SPT threshold were 
increased, and most of the patients experienced transient adverse 
reactions after OIT treatment. Therefore, this study did not provide 
a clear evidence of tolerance induction. Keet et al. showed that 40 % 
of subjects receiving milk OIT passed an oral food challenge when 
treatment was ceased for 6 weeks, however some regained reactivity 
within a week [16]. Similar results were observed in OIT with egg 
and peanut allergens [17,18]. Although data on long-term treatment 
are limited, Keet et al. showed that, three to five years after cow´s 
milk OIT was finished, only 25% of subjects were consuming normal 
amounts of milk without any symptoms, and that almost 20% of 
treated patients experienced anaphylactic reactions during the 
follow-up period, including children who appeared to have a good 
response to treatment [19]. 
Additionally, peanut allergy is the most common cause of fatal 
food allergic reactions [20] since peanut components are widely 
used in processed foods, and some of them were probed to be highly 
immunogenic [21]. This means that fatal or nearly fatal reactions 
to this life-threatening allergen are responsible for several deaths in 
the United States (thousands of hospitalizations and hundreds of 
fatal cases per year) following accidental exposure to this allergen 
[22,23]. Although, there are no immunotherapy regimens in routine 
use for peanut allergy, peanut OIT has showed promising results. 
Most peanut OIT protocols involve an initial escalation phase (days) 
of orally administered peanut. This is followed by administration 
of further build-up doses (months), and then maintenance doses 
(months). The maximum maintenance doses are between 300 mg and 
4000 mg of peanut protein. While some studies have shown hopeful 
results, the risk of severe reactions during allergen administration 
is of concern [24,25]. Anagonostou et al. have investigated the role 
of peanut OIT in 99 children with peanut allergy in a phase II, 
randomized-controlled trial. Subjects who successfully completed the 
OIT protocol had a 25-fold increase of their peanut threshold [26]. 
Despite the number of promising OIT studies and the increasing 
interest of the medical community in the development of a routine 
OIT using native proteins, a high percentage of patients still suffer 
adverse side effects. One of the therapeutic strategies assessed to 
overcome it was to include modified allergenic proteins (baked 
or roasted) in the sequential steps of allergen administration. The 
addition of baked milk or egg to the diet of allergic children that 
tolerated such baked foods accelerated the development of tolerance 
to unbaked milk or egg compared with patients that did not tolerated 
the processed food and received a free-allergen diet [27,28]. It was 
observed that this procedure induced mild adverse reactions, which 
were easily controlled.
In summary, OIT has showed promising results in cow´s 
milk, peanut and egg white allergen patients, with the primarily 
induction of desensitization and further tolerance. However, the 
high rate of adverse reactions elicited during the immunotherapy, 
and the uncertainty of long term outcome require further studies. 
Furthermore, the immunological mechanisms underlying 
desensitization and tolerance mechanisms in OIT have not been 
fully investigated (Table 1). In this sense, experimental animals may 
provide relevant information in a way that would be nonviable in 
clinical trials. 
A relatively new form of non-specific immunotherapy is the 
Immunotherapy Study Antigen Mechanism References
OIT
Human
Peanut
Milk
Egg
Treg, IL-10, 
TFG-β
[71-73]
Mouse
Milk
Egg
Peanut
Treg, IL-10, 
TFG-β
[37,74,75]
SLIT
Human MilkPeanut
IL-10, Th1, 
IgG4 [27,76,77]
Mouse -- -- No ref.
SCIT
Human MilkPeanut
Treg, IL-10, 
increase IgA, 
Igg4
[62,63]
Mouse -- -- No ref.
Table 1: Mechanisms induced in antigen-specific immunotherapies.
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anti-IgE therapy (with humanized a-IgE monoclonal antibody-
Omalizumab), which has been successfully used in asthma. Sampson 
et al. started a phase II clinical trial with Omalizumab in 150 patients 
with peanut allergy; however the study was terminated early due 
to the severe reactions that occurred during the peanut challenge 
[29]. Recently, a combination therapy was studied using the a-IgE 
antibody in patients undergoing OIT. It was observed that the 
biological was effective in reducing adverse reactions during the oral 
administration of the allergen (cow´s milk, wheat, peanut and egg), 
with a rapid oral desensitization [30-32]. Although these clinical trials 
were effective for mono-allergic and multi-allergic patients, reaching 
daily doses of 4000 mg for individual allergens during several weeks, 
tolerance was not demonstrated [33]. However, several potential 
benefits can be speculated with the combination of both therapies. An 
additional strategy to reduce the risk of adverse reactions is the use 
of modified allergens. The efficacy of this therapy was evaluated in a 
humanized mouse model [34]. OIT with dietary food produce a high 
rate of adverse side effects, due to the intact B cell epitopes in native 
allergenic proteins with capacity to cross-link IgE bound to mast cell 
and basophil membrane receptors. The use of peptides containing T 
epitopes has been reported to be a safe and effective option for OIT 
in animal models of asthma to mite allergen [35,36] and food allergy 
to egg [37]. Finally, food allergy mouse models were used to test 
mutated allergens, in which immunodominant B cell epitopes were 
modified by point mutation to impair allergenicity, and to develop a 
safer immunotherapy [38-40]. 
Sublingual immunotherapy
Sublingual immunotherapy (SLIT) involves frequent placement 
of micrograms to milligrams of allergen under the tongue. Cochrane 
analyses have confirmed the efficacy and safety of sublingual 
therapy for allergic rhinitis with long-term benefits (1-2 years) [41]. 
Although most of the SLIT studies have focused on inhalant allergies, 
emerging clinical trials with SLIT have shown promising results at 
inducing desensitization in food allergy [42,43]. However, SLIT is 
not currently recommended for treatment of food allergy [44]. Only 
few studies have been done in peanut, nuts, kiwi, peach and cow´s 
milk allergy [45-49] and they showed lower frequencies of adverse 
reactions compared with OIT, which is likely due to lower doses 
of allergen administration and the capacity of the mouth mucosa 
to induce intestinal tolerance. However, the efficacy of SLIT is still 
debated. Considering that the induction of Treg is the key mechanism 
underlying desensitization and tolerance, it has been reported that 
the current protocols of SLIT have a lower efficiency as compared 
to OIT (Table 1) [50,51]. Nevertheless, SLIT protocols used for egg, 
cow´s milk or peanut allergy [52] showed a significant  increase  in 
the threshold dose of the food allergen to induce allergic symptoms, 
a decrease in serum specific IgE along with a rise in serum IgG4 
levels , and induction of Tregs [40]. There are only two randomized 
studies comparing oral and sublingual immunotherapies. Keet et al. 
conducted a clinical trial with 30 milk allergic patients comparing 
SLIT alone versus SLIT followed by OIT. It was reported that despite 
the similar number of total adverse food reactions between groups, 
the number of systemic reaction was higher in the OIT groups. Of 
note, the oral challenge performed after 60 weeks of maintenance 
doses, rendered a higher allergen threshold in SLIT followed by OIT 
treated patients compared with SLIT-treated patients [16]. Narisety 
et al. performed a similar randomized study with peanut allergic 
patients to compare the safety and efficacy of OIT and SLIT. They 
found a partial desensitization with at least a 10-fold increases in 
peanut challenge threshold compared with baseline. They similarly 
found that efficacy of OIT was greater than SLIT, although safety is 
still greater in patients receiving SLIT compared with OIT [18]. 
The literature shows scarce reports exploring SLIT in mouse 
models. Most of them employed mucosal adjuvants and were done 
in rhinitis and asthma. Lombardi et al. showed that Pam3CSK4, a 
known TLR2 agonist, exhibits immunomodulatory properties with 
the induction of CD4+ T cells that secreted IL-10 and IFN-γ to control 
the allergic reaction [53]. Saint Lu et al. used a mucoadhesive form of 
chitosan to enhance allergen uptake, processing and presentation by 
dendritic cells. It was shown that the treatment enhances tolerance 
induction in mice with established asthma, with a reduction of lung 
inflammation [54]. Of note, there is no study with experimental 
animals using SLIT to show that immunomodulatory mechanisms 
can be induced in the sublingual mucosa, with the subsequent 
control of the intestinal inflammation and the systemic allergy. Based 
on our preliminary data showing that the sublingual administration 
of the allergen, or the allergen in combination with Th1 adjuvants, 
can control hypersensitivity symptoms upon allergen oral challenge, 
we consider that food allergy mouse models are indeed a valuable 
biological tool to study pre-clinical strategies for food allergy 
immunotherapy. Using a cholera toxin-driven IgE-mediated milk 
allergy model, we could revert an established Th2-biased intestinal 
immune response with the oral administration of milk proteins, and 
the subsequent induction of Tregs (data not published).
In summary, SLIT in humans has been clearly associated with a 
substantially reduced risk of adverse reactions, although efficacy and 
long-term effectiveness are the main drawbacks. Food allergy mouse 
models may provide information for new hopes to improve this 
disease-modifying therapy. 
Subcutaneous and epicutaneous immunotherapy 
The major form of allergen-specific immunotherapy is the 
subcutaneous immunotherapy (SCIT). Subcutaneous injections of 
the allergen deliver the allergen to skin Langerhans cells, with the 
subsequent migration of dendritic cells to lymph nodes and further 
regulation of effector allergic responses [55]. Although, it is widely 
used for treatment of allergy, it is not accepted as a routine therapy, 
especially for children. Recruitment of patients and then (less that 5% 
of all allergic patients) compliance to SCIT (less than 25% of patients 
drop out within the first year of treatment) are difficult to achieve 
[56].
Safety and effectiveness of SCIT have been reported in rhinitis and 
asthma [57]. Although adverse reactions have been documented, the 
vast majority are mild and very rarely fatal [58]. In contrast, clinical 
trials of SCIT in peanut allergic patients showed that anaphylactic 
side-effects induced during the administration of the native allergen 
are highly frequent [59,60]. The first attempt to improve this protocol 
was done by The European multicenter consortium that conducts the 
prospective Food Allergy Specific Immunotherapy (FAST) project to 
evaluate the use of alum-adsorbed hypoallergens to control fish and 
peach allergy. Recombinant mutated allergens, with decreased IgE-
binding capacity and intact T cell-reactivity capacity, are included in 
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the SCIT. Patients will be enrolled for a phase I/IIA initial clinical 
trial, while animal models will be used to evaluate the allergenicity 
of the recombinant hypoallergenic proteins developed and efficacy of 
the immunotherapy [61]. 
More recently, epicutaneous immunotherapy (EPIT) with 
allergen-embedded patch administration has been carried out in food 
allergy. One of the first clinical trials for EPIT evaluated 18 children 
with cow´s milk allergy during three months. EPIT not showed 
serious systemic adverse effects. Although treatment was associated 
with more frequent complaints for local pruritus and discomfort 
than placebo, patient compliance was not compromised [62]. In 
addition, there is a phase I clinical trial that is conducted in the 
United States with 80 peanut allergic patients that received EPIT and 
20 placebo-treated subjects; mild or moderate local adverse effects 
were experienced by 90% of patients [63]. Another clinical trial in 
phase IIA with 54 children with peanut allergy that underwent EPIT 
showed a good response. Oral food challenges conducted at 6-month 
intervals over a 18-month period revealed that 67 % of patients 
achieved desensitization, with a 10-fold increase in cumulative 
reactive dose from baseline [64,65].
Despite the scarce number of reports, studies of allergen patch in 
animal models indicate a potential application of this therapy. Pre-
clinical studies in mice were carried out with peanut, ovoalbumin 
and some aeroallergens using a skin patch [66-68]. EPIT on intact 
skin down-modulated the allergic immune response through the 
induction of long-lasting tolerogenic Treg [69]. The protection 
offered by EPIT-induced Tregs was adoptively transferred to peanut 
sensitized animals [68,70]. 
Remarkably, there is no study of SCIT in animal models, thus 
reflecting the difficulty to immunomodulate allergic disorders 
through this administration route in mice. 
Conclusions
Immunotherapy appears to be a promising option for the 
treatment of food allergy. OIT and SLIT have emerged as attractive 
therapies to divert the aberrant immunological mechanisms 
underlying these diseases. Both modalities have shown to induce 
desensitization through different mechanisms (Table 1). Although 
it has been demonstrated that a sustained unresponsiveness can be 
achieved with OIT, several clinical trials support that safety, feasibility, 
compliance, and economic profile is mainly found with the sublingual 
immunotherapy. However, further research is needed to improve its 
efficacy and long-term effectiveness. In this scenario, mouse models 
represent a valuable tool for evaluating novel or modified forms of 
immunotherapy and also for dissecting the mechanism of action. 
The combination of specific methods or even both specific and non-
specific methods may enhance desensitization with a rapid onset of 
tolerance.
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